Re:Esketamine Drug For Depression Treatment Nears FDA Approval
by WalterSear on Tuesday February 12, 2019 @07:11PM
(#19149064)
It's even more confusing: R-ketamine is the more effective enantiomer, with less dissociative effects.
[ Parent
| on HN ]
Re:Esketamine Drug For Depression Treatment Nears FDA Approval
by civilian on Tuesday February 12, 2019 @07:51PM
(#19149336)
Sweet, I like that J&J is using S-ketamine then. I think the dissociative effects of ketamine are fantastic and beneficial, even though they can be surprising. At a low dose it likely won't be an issue.
Re:Esketamine Drug For Depression Treatment Nears FDA Approval
by WalterSear on Wednesday February 13, 2019 @03:26PM
(#19156613)
Personally, I have no issues with the dissociative effects per se. However, studies have determined that they aren't related to the antidepressant effect. Fwiw, a full clinical dose feels like ~1/4 of a 'rail'. There's no introspective trip here, just slight drunkenness.
(Incidentally, we have some evidence that the metabolite that causes the effect can be blocked via concurrent CBD administration - without reducing the dissociative effect)
The standing appointment to get slightly high for a couple of hours every three days does get inconvenient (though it's not as problematic as the resultant insomnia). I expect esketamine will be more so, for less antidepressant effect. And, being a controlled substance, I'm concerned I'll be unable to increase my dosage to make up the difference.
Re:Esketamine Drug For Depression Treatment Nears FDA Approval
by rincebrain on Wednesday February 13, 2019 @08:18AM
(#19152781)
People seem to still be arguing about that - [1] and [2] argue that they're directly correlated in ketamine treatment, and I can't begin to guess what research on {ar,es}ketamine and metabolite efficacy is going to produce when one of these becomes readily available.